TrialClinical pharmacokinetics2009

Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma.

David I Quinn et al.PubMed ↗Publisher ↗

No numbers read from the abstract.